The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy

BACKGROUND: Relapsing Remitting Multiple Sclerosis (RRMS) patients treated with interferon beta (IFN beta) can develop neutralizing antibodies (NAbs) that reduce treatment efficacy. Several clinical studies explored the association of NAb+ status with increased disease activity. OBJECTIVE: The aim o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:PLoS One
Main Authors: Paolicelli, Damiano, Iannazzo, Sergio, Santoni, Laura, Iaffaldano, Antonio, Di Lecce, Valentina, Manni, Alessia, Lavolpe, Vito, Tortorella, Carla, D'Onghia, Mariangela, Direnzo, Vita, Puma, Elisa, Trojano, Maria
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2016
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4938389/
https://ncbi.nlm.nih.gov/pubmed/27390865
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0159214
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados